Case report details dog’s survival after refractory VT and CPR: full analysis

Version 2

A newly published case report details a successful functional outcome in a young dog with ventricular tachycardia after an unusually intensive resuscitation sequence: multiple antiarrhythmics, attempted cardioversion, prolonged CPR, defibrillation, and intra-arrest intravenous lipid emulsion. The patient, a 6-month-old American Cocker Spaniel, ultimately survived 16 minutes of cardiopulmonary resuscitation and was still doing well 12 months after discharge on mexiletine and sotalol. The report appears in the Journal of Veterinary Emergency and Critical Care and comes from clinicians at the University of Wisconsin–Madison. (pmc.ncbi.nlm.nih.gov)

The case stands out because sustained ventricular tachycardia in dogs can be difficult to stabilize, especially when rhythm control attempts and drug therapy begin to collide with hemodynamic instability. In veterinary cardiology, lidocaine is still a mainstay for acute ventricular arrhythmias in dogs because of its rapid onset and short half-life, while mexiletine and sotalol are familiar longer-term options for chronic control. Reviews of canine ventricular arrhythmia management also note that synchronized electrical cardioversion may be considered when rapid sustained ventricular tachycardia is refractory to drug therapy, but generally as a last-resort measure in unstable patients. (merckvetmanual.com)

According to the case report, clinicians suspected lidocaine toxicosis during the arrest and administered intravenous lipid emulsion during CPR. The dog then achieved return of spontaneous circulation and recovered with a favorable neurologic and functional outcome. That matters because the report ties together two areas where the evidence base is still relatively thin in veterinary medicine: management of refractory shockable rhythms, and rescue use of lipid emulsion for lipophilic drug toxicity during active resuscitation. (pmc.ncbi.nlm.nih.gov)

The broader clinical backdrop has shifted somewhat in the past two years. The 2024 RECOVER advanced life support guidelines state that in dogs and cats with a shockable rhythm that does not respond to initial defibrillation, clinicians should double the defibrillator dose once and may use vasopressin or epinephrine, esmolol, lidocaine in dogs, and amiodarone in cats. The updated RECOVER materials also explicitly say the revisions were intended to clarify management of refractory shockable rhythms and prolonged CPR. That doesn’t amount to an endorsement of lipid emulsion in arrest, but it does place this case in a practice environment that is paying closer attention to prolonged, protocol-driven resuscitation in selected patients. (pubmed.ncbi.nlm.nih.gov)

On the lipid emulsion side, the veterinary literature is mixed but growing. Reviews and case series describe ILE as a rescue therapy for severe intoxications involving lipophilic compounds, including local anesthetics such as lidocaine, and some authors conclude it should be considered in severe intoxications. But larger retrospective veterinary data sets also show that adverse effects can occur, and published case reports have linked ILE to serious complications including suspected acute respiratory distress syndrome. In other words, the intervention is established enough to be on many emergency clinicians’ radar, but not settled enough to be routine in every unstable arrhythmia case. (pmc.ncbi.nlm.nih.gov)

Why it matters: For emergency and critical care teams, this report is a reminder that a poor rhythm event in a young dog isn’t always futile, especially when the underlying problem may be reversible and the team can escalate quickly across pharmacologic and electrical options. For cardiology services, it reinforces the practical role of mexiletine plus sotalol in post-discharge rhythm control. For general practitioners and ER referral networks, the takeaway is narrower but important: when repeated lidocaine exposure is part of acute VT management, clinicians need to keep toxicosis on the differential even while treating a life-threatening arrhythmia. (pmc.ncbi.nlm.nih.gov)

The case should not be overread. It is a single report, not a comparative study, and it can’t tell clinicians whether lipid emulsion changed the outcome, whether defibrillation timing was the decisive factor, or which patients are most likely to benefit from similarly aggressive care. Still, case reports often shape bedside awareness before stronger evidence arrives, and this one may influence how specialists think about rescue options when refractory ventricular arrhythmias and suspected antiarrhythmic toxicosis overlap. (pmc.ncbi.nlm.nih.gov)

What to watch: The next signal to watch is whether additional case reports, retrospective series, or future RECOVER evidence reviews begin to address intra-arrest lipid emulsion more directly in dogs with suspected local anesthetic toxicosis or refractory shockable rhythms. (pubmed.ncbi.nlm.nih.gov)